NCT00493857View on ClinicalTrials.gov

Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

December 31, 2008

Conditions
Colorectal Cancer
Interventions
DRUG

Nimotuzumab Humanized Monoclonal Antibody

Nimotuzumab 400mg every week

DRUG

Nimotuzumab

Nimotuzumab 400mg every 2 weeks

Trial Locations (12)

T2N 4N2

Tom Baker Cancer Center, Calgary

R3E 0V9

Cancer Care Manitoba, Winnipeg

A1B 3V6

Dr. H. Bliss Purphy Cancer Centre, St. John's

L4M 6M2

Royal Victoria Hospital, Barrie

N2G 1G3

Grand River Hospital, Kitchener

N6A 4L6

London Regional Cancer Centre, London

L5M 2N1

Credit Valley Hospital /Carlo Fidani Peel Regional Cancer Centre, Mississauga

Unknown

Cancer Care Program Southlake Regional Health Centre, Newmarket

K1H 1C4

Ottawa Regional Cancer Centre, Ottawa

P6A 2C4

Algoma District Cancer Care Program, Sault Ste. Marie

M4N 3M5

Sunnybrook Regional Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

YM BioSciences
All Listed Sponsors
lead

YM BioSciences

INDUSTRY

NCT00493857 - Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter